Sales and profit outlook upgradedAll divisions contributingStrategic plans paying offGlobal medical products company Convatec (CTEC) jumped 20% to top the FTSE 100 leaderboard after upgrading full year sales growth and margin guidance in an unscheduled trading update.It is one of the biggest one-day advances in the shares since the business listed on the stock market in 2016 and means they are out

Stock prices in blue chip indices in London, Paris and Frankfurt were in the red on Tuesday morning, as traders digest an increasing likelihood that incoming US president Donald Trump will enact punitive tariffs and a very hawkish stance on China.'The latest moves from Trump's camp, especially with China hawks joining his inner circle, are sending chills through the markets and casting a decidedly

Organic revenue up 6.5% in Q1Advanced wound care outlook cutFull-year outlook maintainedShares in Convatec (CTEC) fell 4% to 255.7p after the medical products maker flagged short-term uncertainty in Advanced Wound Care leading to a softer outlook for the division.The news took the shine off a strong start to the year with first-quarter organic revenue up 6.5% which was slightly ahead of market for

Full year sales and profit beat estimatesMedium term guidance raisedImproved commercial executionShares in medical products company Convatec (CTEC) traded 7% higher to 270p after full year sales and profit came in ahead of market expectations and management raised guidance.The shares registered new 12-month and five-year highs which means they have doubled over the last five years compared with a

Organic sales growth acceleratesFull-year growth targets increasedNo impact seen from obesity drugsMedical products company Convatec (CTEC) continues to generate strong organic sales growth, prompting management to increase its full-year sales and earnings guidance for a second time.The shares responded positively, gaining 3% to 214.8p leaving them down around 8% year-to-date. Sales for the

Snap up medical products outfit ConvaTec (CTEC) as a multi-year turnaround gains traction. Recent evidence for this came as the company raised full year guidance for the second time this year (2 August), delivering accelerated revenue growth in the six-month period to 30 June.After a downward trend in the share price, the positive news has helped to turn the tide and we think this could be the pre

Stocks in Europe were rocked by Fitch lowering its US rating on Wednesday, evoking memories of S&P doing the same almost 12 years ago to the day.Stocks suffered then, and they similarly struggled now. Barely a handful of London's 100-strong flagship large-cap benchmark were on the up, with BAE Systems among those shielded by the fallout after it boosted guidance.'There is a saying that when the US

Full year organic sales growth guidance raised to a new range of 6% to 7.5%Adjusted operating profit margin guidance increased to 20.5%Medium term operating margin target in mid-20% rangeThe multi-year turnaround at medical products company Convatec (CTEC) finally seems to be gaining traction after the company raised full year guidance for the second time this year and delivered accelerated revenu

Good start to 2023 against tough prior year comparisonFull year organic sales guidance increasedOn track with new product launchesMedical products group ConvaTec (CTEC) said it has made a good start to the year after registering organic sales growth of 3.1% in the first four months to 30 April, against a tough prior year comparative.The company said improving momentum and confidence in the outlook

Convatec head sells shares to meet tax liabilitiesFerro-Alloy Resources chief buys over £600,000 sharesMorgan Advanced Materials director snaps up 35,000 sharesConvatec Group (CTEC) chief executive Karim Bitar has sold 429,441 shares at 216p for £929,479 on 2 May to meet income tax and social security liabilities.The medical products and technologies company based in Reading sells various produc

- Index changes to be announced tonight- Three new names to join the FTSE 100- Four new faces in the mid-cap FTSE 250Investors with FTSE tracker funds will be keenly waiting for details of the latest index reshuffle due to be published after the market close tonight.As well as changes to the FTSE 100 big-cap index there are expected to be several changes to the FTSE 250 mid-cap benchmark and the F

- Treatt chairman buys stock after profit warning- The company's CEO also buys shares- ConvaTec non-exec buys after better-than-expected resultsTwo directors bought shares in flavour and fragrance ingredients maker Treatt (TET) on 15 August in the wake of a profits warning which sent shares sliding by over 30%.Chairman Tim Jones purchased 8,944 shares across, taking his total interest to 67,032 sh

- First half earnings beat estimates- Convatec confirms full year guidance- Advanced wound care and infusion care the strongest divisionsInvestors welcomed the latest trading update from medical solutions firm Convatec (CTEC), lifting the shares 7.3% to a new 12-month high of 247p.While the headlines weren't market-moving, the fact the company confirmed its full year guidance raised hopes it was m

Global medical solutions group Convatec (CTEC) said it has made a good start to the 2022 financial year with organic revenues up 6% year-on-year.Despite raising guidance on cost inflation to between 8% and 9% compared with 5% previously, the company reiterated full-year guidance.That is, organic revenues are anticipated to grow between 4% and 5% with an operating margin of at least 18%.HOSPITAL CA

The transformation of medical technology company ConvaTec (CTEC) has reached an inflection point which should drive market-beating sales growth and improve profitability.The shares look attractive against good earnings potential while scope for the stock to trade on a higher multiple of earnings (known as a 're-rating') provides extra attractions. This could be driven by a modest improvement in op

Wound Care and medical solutions firm ConvaTec (CTEC) has agreed to acquire Triad Life Sciences Inc for an initial $125 million, strengthening the company's US Advanced Wound Care business.Investors gave the acquisition a warm reception, marking the shares up 1.3% to 170.2p.ConvaTec said the deal gives it entry into the large and fast-growing biologics segment of the wound care market which is wor

Constructed last December from shares in UK, European and US markets, Shares' 'Stock picks for 2021' portfolio was based on high conviction in 12 companies for the year ahead. While more than half of them have subsequently done well, there were a handful of disappointments.The net effect is a decent 8.6% return excluding dividends - that's higher the historical average 6% to 7% from equities inclu

There is no reason why a share must open at the previous night's closing price. Daily price moves are determined by supply and demand for the shares and that in turn is affected by company news such as earnings updates, acquisitions, disposals, legal disputes, new product launches and so on.In fact anything which changes the fundamentals or investor sentiment towards a company has the potential to

The UK equity market ended Friday's session on a weaker note with the FTSE 100 Index closing down 0.16% at 7237.5, while the FTSE 250 Index fell by 0.4% to finish at 23,106.61.The technology heavy American Nasdaq index drifted lower and failed to provide any support to the UK market. This was in response to disappointing results from Amazon. A rise in costs as the company moves into 'heavy investm

The UK equity market continued to trade lower by lunchtime on Friday with the FTSE 100 off 0.25% at 7,231.48 points and the FTSE 250 falling by 0.23% to 23,145.67.The market was uninspired by NatWest's (NWG) third quarter results, with market weakness compounded by supply chain-related warnings from technology leviathans Apple and Amazon.Fantasy miniatures maker Games Workshop (GAW) also impacted